Avalon clinches majority investment to expand future of diagnostic intelligence
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
Improvements were also seen in complete response rates, duration of response, and time to next treatment
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Over 8.8?million Indians aged 60 and above currently live with dementia,
India in the Changing Landscape of Life-Sciences Research & Development
The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers
Subscribe To Our Newsletter & Stay Updated